When It Comes To Complex PTSD, Depression, Research Turns to Psychedelics For Treatment

People struggling with treatment-resistant PTSD may soon have a new course of care: MDMA. When used alongside psychotherapy, the synthetic substance in the drug more commonly known as ecstasy or molly is currently in phase three clinical trials. It’s even been given “breakthrough designation” by the FDA, a status reserved for treatments with significant potential to improve patient outcomes. But MDMA isn’t the only kind of party drug experiencing interest for therapeutic potential. Psilocybin, the active ingredient in "magic mushrooms", is being evaluated for its potential in alleviating depression. Guided ayahuasca trips are a growing trend, especially amongst Brooklyn and Silicon Valley elites.